Why Farbe Firma is the Top Manufacturer of Sodium Valproate Injection
- Maulik Sudani
- 22 hours ago
- 8 min read
Last Updated: June 17, 2026
TL;DR: Sodium Valproate Injection — a sterile aqueous solution (or lyophilized powder for solution) of sodium valproate, a broad-spectrum anticonvulsant and antiepileptic, supplied commonly as a 400 mg vial (with solvent) or as a 100 mg/mL solution for intravenous bolus and infusion — is the standard hospital agent for the control of status epilepticus and for continuing valproate therapy when the oral route is temporarily unavailable. Because the patient is often critically ill and the molecule is highly hygroscopic, alkaline in solution and strictly contraindicated in pregnancy, each vial must deliver an exact, sterile, particulate-free dose at the labelled concentration with unambiguous teratogenicity warnings, with the assay, the impurity and degradation profile, solution pH, residual moisture where lyophilized, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Sodium Valproate Injection at our Gujarat, India facility and supplies it to emergency, neurology, intensive-care and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Broad-spectrum anticonvulsant / antiepileptic (sodium salt of valproic acid) — Sodium Valproate Injection is given intravenously, as a slow bolus or infusion, for the control of status epilepticus and to maintain valproate therapy when oral dosing is temporarily not possible, with prominent teratogenicity warnings governing use in women of childbearing potential.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated compounding and vial filling (and, where lyophilized, freeze-drying) lines, control of the stability-indicating assay, the impurity profile, solution pH, residual moisture, fill volume, particulate and endotoxin under low-humidity handling for a hygroscopic active, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution and lyophilized contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready vial packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Sodium Valproate Injection Demands a Premium Manufacturer
Sodium Valproate Injection holds a critical, time-sensitive place in emergency departments, neurology services and intensive-care units across every market. It is the intravenous anticonvulsant that clinicians reach for to bring status epilepticus under control and to continue established valproate therapy in a patient who cannot, for the moment, swallow tablets — after surgery, during critical illness, or while unconscious. As a broad-spectrum antiepileptic active across multiple seizure types, valproate is a mainstay of seizure management, and its injectable form lets a treating team move from oral to intravenous and back without interrupting therapy. In each of these settings the dose delivered from each vial must be exact, sterile, particulate-free and reliably the same from unit to unit, because rapid, dependable seizure control depends on a precise, reproducible dose given without delay.
That clinical reality places real demands on the manufacturer. Sodium valproate is highly hygroscopic and its solution is markedly alkaline, so the product — whether presented as a ready aqueous solution or as a lyophilized powder reconstituted before use — must be compounded, filled and, where freeze-dried, sealed under tightly controlled low-humidity conditions, with residual moisture held within a defined limit so the product stays stable across shelf life. The assay of sodium valproate must be exact; the impurity and degradation profile must stay within tight limits; the solution pH and the deliverable volume must be controlled so each vial gives the labelled dose at the labelled concentration; the solution must be free of visible and sub-visible particulates and low in endotoxin. Above all, because valproate is a recognised human teratogen, the labelling, the package insert and the artwork must carry unambiguous pregnancy and pregnancy-prevention warnings in every market language. Choosing a Sodium Valproate Injection manufacturer that treats low-humidity and residual-moisture control, the stability-indicating assay, pH and particulate control, teratogenicity labelling and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Sodium Valproate Injection Manufacturer Apart
A world-class manufacturer of Sodium Valproate Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of sodium valproate with related-substance and degradation control by validated chromatography (HPLC, with GC suited to this simple fatty-acid molecule) that an emergency antiepileptic demands, a robust, validated sterilisation and fill process — aqueous-solution filling or low-humidity lyophilization with controlled residual moisture — that protects sterility, pH and stability in a hygroscopic active, and tender-ready dossier support for a high-volume hospital-formulary product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade sodium valproate sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay against moisture and the pH against drift. The bulk solution is compounded in water-for-injection at the controlled alkaline pH that keeps valproate soluble and stable, sterile-filtered through 0.22 µm membrane, and filled into vials under ISO Class 5 conditions; where the product is presented as a freeze-dried powder, the solution is filled and lyophilized under a validated cycle and the vials sealed under low humidity with residual moisture confirmed by Karl Fischer, the whole hygroscopic-active workflow protected from ambient humidity, with the validated sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — locked in the master batch record. Filled vials are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of sodium valproate by validated chromatography, the related-substance and degradation profile, solution pH, residual moisture where lyophilized, deliverable volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intravenous administration. Because the molecule draws moisture and the solution runs alkaline, residual-moisture control, pH control and container-closure integrity are validated together so assay and pH stay within specification across shelf life.
Quality Systems Behind Every Sodium Valproate Injection
Every Farbe Firma Sodium Valproate Injection batch is released only after a full stack of quality checks: stability-indicating assay of sodium valproate against pharmacopoeial reference standards, control of related substances and degradation products by validated chromatography, solution pH, clarity and colour of the solution, residual moisture by Karl Fischer for lyophilized presentations, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental and humidity monitoring, validated sterilisation, depyrogenation and lyophilization equipment, validated filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because sodium valproate is hygroscopic, alkaline in solution and teratogenic, and the assay, pH, residual moisture, particulate and endotoxin burden of the product drive both efficacy and safety, we treat the stability-indicating assay, the residual moisture, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and reconstitution and in-use stability are established to support emergency intravenous preparation.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Sodium Valproate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad emergency, neurology and critical-care small-volume parenteral portfolio. For Sodium Valproate Injection specifically, we supply the 400 mg vial (with solvent) and the 100 mg/mL solution presentation under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, residual-moisture, pH, sterilisation and container-closure data package, and the teratogenicity risk-management labelling — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork — including pregnancy-prevention warnings — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Sodium Valproate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding, filling and lyophilization suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control, low-humidity handling and residual-moisture control for a hygroscopic active, alkaline-pH formulation design, the choice between terminal sterilisation and aseptic filling, lyophilization-cycle and reconstitution control, deliverable-volume accuracy, teratogenicity labelling that prevents harm in pregnancy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For an emergency antiepileptic where assay accuracy, moisture and pH control, particulate control and clear pregnancy warnings directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Sodium Valproate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Sodium Valproate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated compounding, vial filling and lyophilization lines under low-humidity control, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Sodium Valproate Injection do you supply?
Our standard presentations are the 400 mg vial (supplied with solvent) and the 100 mg/mL solution of sterile sodium valproate, for intravenous bolus and infusion. Custom strengths, fill configurations, vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Sodium Valproate Injection mainly used for?
Sodium Valproate Injection is used for the control of status epilepticus and to maintain valproate therapy when the oral route is temporarily unavailable. It is a broad-spectrum anticonvulsant and antiepileptic; because valproate is teratogenic, its use in women of childbearing potential is governed by strict pregnancy-prevention measures. Farbe Firma verifies the assay, pH, residual moisture, deliverable volume, particulate matter and endotoxin at release so each vial delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Sodium Valproate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork — including pregnancy-prevention warnings — for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Sodium Valproate Injection contract manufacturing?
MOQs vary by strength, vial size, solution-versus-lyophilized presentation, sterilisation route, label complexity and dossier requirements. For our emergency small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments